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ABSTRACT
Advances in oral SERDs development so far have been confined to nonsteroidal 
molecules such as those containing a cinnamic acid moiety, which are in earlystage 
clinical evaluation. ZB716 was previously reported as an orally bioavailable SERD 
structurally analogous to fulvestrant. In this study, we examined the binding details 
of ZB716 to the estrogen receptor alpha (ERα) by computer modeling to reveal its 
interactions with the ligand binding domain as a steroidal molecule. We also found 
that ZB716 modulates ERα-coregulator interactions in nearly identical manner 
to fulvestrant. The ability of ZB716 to inhibit cell growth and downregulate ER 
expression in endocrine resistant, ERα mutant breast cancer cells was demonstrated. 
Moreover, in both the MCF-7 xenograft and a patient derived xenograft model, 
orally administered ZB716 showed superior efficacy in blocking tumor growth when 
compared to fulvestrant. Importantly, such enhanced efficacy of ZB716 was shown to 
be attributable to its markedly higher bioavailability, as evidenced in the final plasma 
and tumor tissue concentrations of ZB716 in mice where drug concentrations were 
found significantly higher than in the fulvestrant treatment group.
INTRODUCTION
Selective estrogen receptor downregulators (SERDs) 
are a class of endocrine agents that act both as estrogen 
receptor (ER) antagonists and ER degraders. Currently 
the only FDA approved SERD is fulvestrant, originally 
indicated for breast cancer progressing after tamoxifen or 
aromatase inhibitor (AI) treatment, but recently approved 
for first line endocrine therapy [1–4]. While fulvestrant has 
proven clinically effective with manageable adverse side 
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effects, the drug is well known for its poor bioavailability 
[5]. It can only be administered as a monthly intramuscular 
injection and is believed to have limited drug exposure 
and ER turn-over in patients [6–7]. In the second and 
greater line setting, the low bioavailability of fulvestrant 
and its slow action may in particular contribute to limited 
efficacy because the endocrine-resistant tumor requires an 
even higher drug exposure [8–11]. In the first line setting 
fulvestrant’s route of i.m. administration and the long time 
it takes to reach steady state drug concentration in systemic 
circulation may limit its wider clinical application. Orally 
bioavailable SERDs, therefore, are highly desirable with 
potential to bring substantial clinical benefits to patients 
in need of endocrine therapy, especially in the advanced 
metastatic setting.
Advances in oral SERDs development so far have 
been confined to nonsteroidal molecules among which the 
most promising SERDs are those containing a cinnamic 
acid moiety, believed to be a critical structural feature 
conferring SERD-like properties [12]. Several oral 
SERDs have entered clinical trials since 2014, including 
GDC-0810 and AZD9496 [13–14]. These compounds 
have shown promising preclinical results, including 
strong antiestrogenic activity, ER downregulating 
efficacy comparable to fulvestrant, and favorable 
pharmacokinetic profiles. Their clinical performance, 
however, has yet to be proven. Notably, the dose chosen 
for phase II trial of GDC-0810 [15], at 600mg per day, 
is indicative of its high concentration requirement to 
be therapeutically effective and/or relatively modest 
bioavailability in patients demonstrated in the phase I trial 
[13]. Such high dose requirement may add to its potential 
gastrointestinal tolerability challenge in subsequent 
clinical development [16].
ZB716 is an orally bioavailable SERD that is 
structurally analogous to fulvestrant but modified by 
replacing the 3-hydroxyl group with a boronic acid 
moiety [17] (Figure 1). The rationale for this chemical 
design was based upon previous work [18–20] where 
boronic derivatives of phenolic compounds were found 
to confer much greater oral bioavailability by avoiding 
first-pass metabolism. We showed that ZB716 largely 
retained the pharmacological properties of fulvestrant 
but with vastly improved oral bioavailability [17]. 
Indeed, ZB716 afforded over 10 times higher plasma 
peak concentrations after single-dose oral gavage than 
same-dose fulvestrant administered subcutaneously 
in mice. Here, we first examine the binding of ZB716 
to ER alpha (ERα) in comparison with fulvestrant to 
better understand the remarkable similarity between 
the binding affinities of the two molecules as reported 
previously. Next, efficacy studies demonstrate that orally 
administered ZB716 is effective in blocking the growth 
of MCF-7 derived xenograft tumor and patient derived 
ER+ breast tumor in mice. Compared to fulvestrant, 
ZB716 demonstrates significantly improved tumor tissue 
exposure to drug, consistent with enhanced drug levels in 
systemic circulation. Pharmacokinetic studies in both mice 
and rats confirm high oral bioavailability and sustained 
steady-state drug concentration in blood stream. These 
remarkable improvements over fulvestrant make ZB716 
an excellent steroidal oral SERD with the potential to enter 
clinical trials as first of its kind. It is also anticipated that 
given its known mode of action and adverse side effects 
likely similar to fulvestrant, ZB716 may offer a clearer 
path to the clinic than the nonsteroidal SERDs undergoing 
clinical trials.
Figure 1: Structures of ZB716 and fulvestrant.
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RESULTS
The binding of ZB716 to ER as studied by 
molecular modeling
Having found both fulvestrant and its boronic 
acid derivate (ZB716) bind ER
α
 with comparable 
binding affinities (EC50 3.8 nM vs EC50 4.1 nM)[17], 
we compared the binding of fulvestrant and ZB716 to 
ER
α
 in the antagonistic conformation using molecular 
docking method. Our study shows (Figure 2) that both 
fulvestrant and ZB716 can bind to the antagonistic ligand 
binding site of ERα with high compatibility. As seen in the 
crystal structures of ER in complex with other antagonists 
[21–24], the steroidal moiety of the fulvestrant molecule 
(Figure 2A) binds exactly in the same region as the main 
scaffold of the antagonistic ligands, which is almost 
identical to the binding of estradiol to ERα [25]. The 
fluropentyl sulphinyl containing long linker chain was 
found to protrude through the opening region constituted 
by helix 10/11, helix 12 and helix 4/5. Placement of the 
linker chains in the opening region of helix 10/11, helix 12 
and helix 4/5 of ERα was also seen for other antagonists, 
like 4-hydroxytamoxifen (3ert.pdb), [6-hydroxy-2-(4-
hydroxyphenyl)-1-benzothien-3yl] [4-(2-phrrolidin-1-
ylethoxy)phenyl]methanonone (2r6y.pdb) and the crystal 
ligand used in the present study (2ayr.pdb). At one end of 
the binding pocket, the 3-hydroxyl group of the fulvestrant 
formed hydrogen bonds with Glu353 and Arg394. These 
hydrogen bonds are conserved in many ER-antagonist and 
ER-agonist complexes, including 4-hydroxy tamoxifen 
and estradiol [21, 23–25]. The hydroxyl group on the 
cyclopentane ring of fulvestrant reached out to the other 
end of the binding pocket and got solvated by water 
molecules. The four hydrocarbon rings of the estradiol 
moiety of fulvestrant formed van der Waals contact with 
several hydrophobic residues as shown in Figure 2A. The 
sulfonyl group of the linker forms a hydrogen bond with 
Lys529 and enhances the passing of the linker through the 
opening region.
ZB716 (Figure 2B) also binds to ERα in a similar 
manner as fulvestrant. Though the hydroxyl group was 
replaced with a boronic acid group, the placement of 
the estradiol moiety of ZB716 in the binding pocket and 
hydrogen bond formation with Glu353 and Arg394 were 
observed as in fulvestrant (Figure 2A). This was achieved 
because of the smaller size of boron, and it required 
only a slight (0.7Å) shifting of the molecule along the 
binding pocket as seen in the superimposed structures of 
fulvestrant and ZB716 (Figure 2C). The docking scores for 
both drugs are comparable at -10.85 and -11.28 kcal/mol 
for fulvestrant and ZB716, respectively. Similarly the free 
energies of binding obtained by MMGB/SA calculations 
are also comparable to each other and they are -181.39 and 
-183.41 kcal/mol for fulvestrant and ZB716, respectively. 
A comparison of the binding of fulvestrant and ZB716 
with the crystal structure of antagonists in complex with 
ERα (Figure 2D) showed a similar binding pattern.
Compound-induced modulation of ERα-
coregulator interaction
Molecular modeling shows highly similar ERα-
binding modes of fulvestrant and ZB716. This suggests 
that upon binding to the ligand binding pocket both 
compounds induce a similar ligand-binding domain (LBD) 
conformation and affinity for coregulator proteins. To 
test this, we measured binding of ERα LBD to a peptide 
microarray containing 154 individual (CoR-) NR-boxes 
of a set of 60+ coregulators in absence (apo) or presence 
of compound.
Per compound, the effect was assessed by 
calculation of the modulation index (MI), i.e. compound-
induced log-fold change of binding, for the interaction of 
ERα with each individual coregulator motif. As shown 
in the heat map of Figure 3, this results in a modulation 
profile (column) per compound of 154 interactions 
that are either potentially enhanced (red) or decreased 
(blue). To visualize (dis)similarities between compounds 
(and coregulator interactions) we applied hierarchical 
clustering.
When using the agonist 17-β-estradiol (E2, 
bottom row) the majority of affected interactions show 
enhancement of ERα binding, as illustrated by the cluster 
of motifs at the top half of the heat map. This cluster is 
highly enriched for motifs from coactivator proteins, i.e. 
enhancers of transcription, as can be expected from receptor 
stimulation with an agonist. The lower sub-cluster of E2-
enhanced interactions largely consists of motifs from the 
members of the Nuclear Receptor Coactivator (NCOA) 
family. Alternatively, the interaction of ERα with these 
same motifs is strongly reduced upon incubation with 
antagonists 4-hydroxy-tamoxifen (4-OHT), fulvestrant or 
ZB716. The full modulation profiles are clearly differential 
between compounds with agonist and antagonist behavior. 
Moreover, whereas upon additional comparison of the 
antagonists we observe strong overlap in modulation of 
receptor-coregulator interactions and fulvestrant and ZB716 
are virtually identical, there are clusters of interactions 
that are differentially modulated by 4-OHT. To illustrate 
the observations as described above, we have selected 
ER interactions with some well documented coregulators 
in absence (apo) or presence of indicated compound as 
bar graphs. On the left, E2 strongly enhances binding, 
suggesting strong recruitment of these coregulators to 
the locus of target genes. Alternatively, while the SERDs 
and SERM appear to do the opposite, the y-axis scale is 
largely dominated by E2. We plot the same interactions on 
the right of the heat map with the E2 data to enable further 
comparison of these compounds. While 4-OHT, fulvestrant 
and ZB716 act highly similarly, some of the interactions 
display a moderate differential behavior for the SERDs 
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vs. the SERM. A similar visualization (with or without 
E2) for each individual motif on the array is provided in 
Supplementary Materials (Supplementary Figure 1).
These modulation profiles strongly suggest subtle 
differences in the ERα conformation as induced upon 
binding of 4-OHT and fulvestrant, and more importantly, 
confirm that fulvestrant in vitro pharmacology is 
completely preserved in ZB716 despite the introduction 
of the boronic acid moiety, as was predicted by molecular 
modeling.
ZB716 inhibits cell growth and degrades ER in 
MCF-7 and in T47D/Y537S breast cancer cells
We have previously reported that ZB716 acted both 
as a strong antiestrogen and a potent ER degrader against 
T47D breast cancer cells with IC50 values comparable to 
fulvestrant [17]. Here we show that its action in MCF-
7 breast cancer parallels that in T47D in terms of anti-
proliferative and ER downregulation efficacies. ZB716 
exhibited a dose dependent inhibition of MCF-7 cell 
Figure 2: Binding postures of Fulvestrant, ZB716 and three crystal ligands in the antagonistic binding site of ERα. 
Important amino acids in the binding pockets are shown in stick models, among them the hydrophobic residues are shown in grey, and ERα 
is depicted in ribbon model. Both Fulvestrant and ZB716 form hydrogen bond with Glu353, Arg394 and Lys529. Subset of Figure 2 are 
(A) Fulvestrant in complex with ERα, (B) ZB716 in complex with ERα, (C) superposition of Fulvestrant (yellow) and ZB716 (green) in 
the binding pocket of ERα, and (D) superposition of fulvestrant (yellow), ZB716 (green), 4-hydroxy tamoxifen (cyan), estradiol (magenta) 
and the crystal ligand in 2ayr.pdb (purple) in the antagonistic binding pocket of ERα. Surface representation of fulvestrant and the crystal 
ligand in 2ayr is shown to outline the shape of the binding pocket.
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Figure 3: Modulation of ERα-coregulator interaction by 17-β-Estradiol (E2), 4-hydroxy-tamoxifen (4-OHT), 
fulvestrant, and ZB716. Compound effects are indicated by the modulation index (MI), i.e. compound-induced log-fold change of 
ERα-LBD interaction with peptides representing individual coregulator-derived binding motifs. Enhancement of binding are indicated in 
red while peptide displacement is indicated in blue. Compound and interaction (dis)similarities are visualized by Hierarchical clustering 
(Euclidean distance, Ward’s). Bar graphs display ER binding (mean +/- S.E.M., Arbitrary Units fluorescence) in the absence (apo) or 
presence of compound. The bar color represents the MI. Significance of the modulation is indicated (*p<0.05; **p<0.01; ***p<0.001, 
Student’s t-Test vs. apo).
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growth with an IC50 measured at 3.2 nM, compared to 
fulvestrant at 1.5 nM (Figure 4A). As shown in Figure 
4B, when MCF-7 cells were treated with ZB716 or 
fulvestrant for 4 hours and analyzed for ER expression 
level, downregulation of the hormone receptor occurred 
in a dose-dependent manner consistent with our previous 
observations with T47D cells [17].
To determine if ZB716 is effective as an antiestrogen 
in a clinically relevant breast cancer model that is estrogen 
independent and resistant to antiestrogens, we used an 
ESR1 mutant cell line, T47D/Y537S that was derived 
from a PDX model [26]. Y537S ESR1 mutation has 
been found in recurring advanced breast cancer at high 
frequency [8, 9, 26, 27]. Cells were treated with ZB716 
or fulvestrant at concentrations ranging from 0.1 nM to 
1 μM. As shown in Figure 5A, ZB716 demonstrated a 
dose-dependent inhibition of growth; the IC50 for ZB716 
and fulvestrant was found at 2.44x10-8 M and 3.20x10-8 
M, respectively, about 10 times higher than in the T47D 
cells with wild type ER [17]. We next evaluated the ability 
of ZB716 to downregulate the mutant ER. In Figure 5B, 
downregulation of ER by 50% required approximately 
10 times higher drug concentration, as reflected in the 
IC50 values, which are 24 nM for ZB716 and 11 nM for 
fulvestrant.
ZB716 inhibits growth of MCF-7 human breast 
cancer xenograft in mice
To test the efficacy of orally administered ZB716 in 
vivo, we used an MCF-7 human breast cancer xenograft 
model in nude mice. After the tumor formed and became 
palpable, the animals were randomized into four groups, 
and treated with vehicle, fulvestrant at 200 mg/kg weekly 
Figure 4: (A) MCF-7 breast cancer cells were treated with increasing doses of ZB716 or fulvestrant for 5 days. At the end of treatment, 
surviving cells were counted and normalized to control cells that were treated with vehicle (DMSO) only. (B) IC50 values were obtained by 
deriving logarithmic curves from the %cell survival vs. treatment dose plot.
Oncotarget6930www.impactjournals.com/oncotarget
by subcutaneous (s.c.) injection, ZB716 at 10 mg/kg, or 
30 mg/kg by oral gavage. Tumor sizes were monitored 
and recorded every other day for three weeks of treatment 
duration. As shown in Figure 6A, treatment with ZB716 
resulted in complete blockage of tumor growth at both 10 
mg/kg and 30 mg/kg, indicating that the lower dosage may 
have reached full therapeutic efficacy. We next measured 
the drug concentrations in the plasma and tumor tissues 
collected from mice euthanized at end of study. In the 
fulvestrant treatment group, the only active ingredient 
measured was fulvestrant, whereas in the ZB716 treatment 
groups, both ZB716 and fulvestrant were monitored as 
active ingredients. The average fulvestrant level in the 
final plasma of the fulvestrant treatment group was found 
at 27.92 ng/mL, whereas the average concentration of 
ZB716 and fulvestrant in the ZB716 treatment groups 
were measured at 181.96 ng/mL and 18.35 ng/mL for 10 
mg/kg dose, at 691.88 ng/mL and 144.6 ng/mL for 30 
mg/kg (Table 1). As previously noted, fulvestrant is an 
active metabolite of ZB716, constituting about 10-20% 
of total active ingredients in mice plasma [17]. In the 10 
mg/kg treatment group, the final plasma concentration 
of ZB716 reached 181.96 ng/mL after continuous oral 
administration of the drug, reflective of a steady-state 
Figure 5: (A) T47D-Y537S breast cancer cells were treated with increasing doses of ZB716 or fulvestrant for 5 days. At the end of 
treatment, surviving cells were counted and normalized to control cells that were treated with vehicle (DMSO) only. IC50 values were 
obtained by deriving logarithmic curves from the %cell survival vs. treatment dose plot. (B) Dose-dependent ER downregulation in T47D/
Y537S cells by ZB716 and fulvestrant.
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level that primarily accounts for the superior efficacy 
of ZB716 as compared to fulvestrant treatment. At the 
dose of 30 mg/kg ZB716, plasma levels of both ZB716 
and fulvestrant were further increased, ensuring maximal 
inhibition of tumor growth in mice. We also observed that 
in tumor tissues, accumulation of drugs resulted in a 2-3 
fold higher concentrations than in plasma, significantly 
higher than therapeutically effective levels in breast cancer 
cells (Table 1 and Figure 6B). In addition, tumor tissues 
were also analyzed for ER expression level. Figure 6C and 
6D show the downregulation of ER in tumors from three 
treatment groups of mice.
ZB716 inhibits growth of patient-derived 
xenograft (PDX) tumor in mice
The efficacy of orally administered ZB716 was next 
evaluated in a patient-derived xenograft mouse model in 
which the primary tumor donated by a postmenopausal 
patient was engrafted in NOD scid gamma (NSG™) mice 
(TM00386 PDX model, Jackson Lab). This model has 
been immunohistochemically confirmed as ER+/PR+/
HER2- invasive ductal carcinoma. PDX tumor bearing 
mice were treated with vehicle, fulvestrant 200 mg/kg 
by weekly s.c. injection, ZB716 at 5 mg/kg PO daily, or 
ZB716 at 20 mg/kg PO daily. As shown in Figure 7, ZB716 
at both doses were effective in blocking tumor growth 
in the PDX mice, with the 20 mg/kg treatment group 
showing the greatest effect on tumor growth inhibition. 
Notably, the lower dose of 5 mg/kg demonstrated in vivo 
efficacy in blocking PDX tumor growth as effectively as 
fulvestrant treatment.
ZB716 demonstrates a dose-dependent oral 
bioavailability
When ZB716 was administered to Sprague Dawley 
rats at increasing doses, plasma concentrations of ZB716 
and its active metabolite, fulvestrant, were measured at 
various time points in plasma samples. As shown in Table 
2, for all four doses, ZB716 reached peak concentrations 
in rat plasma at 1 hour after dosing, and the Cmax level 
increased proportionally with dose levels. Notably, the 
peak concentration of ZB716 observed in the 20 mg/kg 
dosage reached over 1000 ng/mL in rat plasma, indicating 
sustainable high oral bioavailability at elevated doses.
DISCUSSION
Clinical challenges facing the current SERD 
regimen for breast cancer therapy include low response 
rate, poor bioavailability, and slow action associated with 
intramuscular injection-only route of administration as 
a 500 mg/10mL oil-based depot. These limitations of 
fulvestrant have driven an intensifying race to a clinically 
proven, orally bioavailable SERD. At least five non-
steroidal SERD candidates have entered phase I clinical 
trials since 2014, yet none has advanced to phase II trials 
except Genentech’s GDC-0810, which unfortunately 
was recently discontinued from an ongoing phase II 
clinical trial due to G.I toxicities. This latest development 
highlights the uncertain clinical path for nonsteroidal oral 
SERDs. Therefore, in order to achieve clinical benefits 
beyond the currently approved fulvestrant, an orally 
bioavailable SERD must satisfy clinical criteria including 
fast action, more durable treatment outcome by virtue of 
high drug exposure, and tolerable adverse side effects. 
Design and development of ZB716 represents a unique and 
promising approach in that it remains as a steroidal SERD 
with minimal structural modifications to vastly improve 
its oral bioavailability. After initially demonstrating its 
in vitro mode of action as a pure antiestrogen and ER 
downregulator in ER+ breast cancer cells and excellent 
oral bioavailability in mice [17], we now report further 
studies of the compound to compare with fulvestrant in 
binding to ER and its efficacy as an oral SERD.
The modeling study of ZB716’s binding mode 
to ERα revealed details of the molecular interactions of 
ZB716 with the ER ligand binding domain that are nearly 
identical to those of fulvestrant. The docking results are 








Fulvestrant Fulvestrant ZB716 Fulvestrant ZB716
Average concentration 
in final plasma (ng/mL) 27.92 18.35 181.96 144.6 691.88
SEM 11.48 11.55 71.72 90.24 283.71
Average concentration 
in tumor tissue (ng/mL) 159.6 67.87 506.1 118.5 1539.67
SEM 47.6 27.03 34.41 109.13 129.33
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helpful in understanding the small differences between 
ZB716 and fulvestrant in their in vitro activities against 
breast cancer cells observed earlier [17], and provide 
further evidence that replacement of the 3-hydroxyl group 
with a boronic acid moiety does not change its binding 
behavior. As a steroidal SERD structurally analogous to 
fulvestrant which has well-established side effect profiles, 
ZB716 may face less toxicological uncertainties in clinical 
trials than the non-steroidal SERDs currently under 
evaluations in patients.
Receptor conformation dictates affinity for and 
recruitment of coregulator proteins to the target gene. 
These coregulators can alter local chromatin accessibility 
for the transcription machinery and eventually determine 
target gene expression levels. Therefore, similarity of in 
vitro coregulator recruitment profiles between ZB716 
and fulvestrant is strongly correlated with similar modes 
of action and pharmacology in vivo. PK/PD factors play 
additional roles in in vivo drug effectiveness, which will 
give ZB716 the competitive edge on top of the effective 
pharmacology that is shared with fulvestrant.
The finding that a higher dose of either fulvestrant 
or ZB716 is required to inhibit the growth of ER mutant 
(Y537S) breast cancer cells underscores the risk of 
insufficient drug exposure in the clinical setting where 
fulvestrant is used to treat recurring diseases that harbor 
ER mutant variants. Consistent with ZB716’s performance 
in other ER+ breast cancer cells, the compound was 
similarly effective in downregulating ER in both breast 
cancer cells with wild type ER and those with mutant 
ER (Figure 5) when compared with fulvestrant. These 
reproducible characteristics of ZB716 in turn are 
anticipated to be translatable to enhanced in vivo efficacy 
owing to its high oral bioavailability as seen in mice [17].
Indeed, the first in vivo experiment using an MCF-
7 mouse xenograft model demonstrated the superior 
efficacy of ZB716 in blocking tumor growth (Figure 6). 
Compared to fulvestrant, which was given as a standard 
200 mg/kg weekly injection, ZB716 was more effective 
at both treatment doses of 10 mg/kg and 30 mg/kg orally. 
Given that ZB716 has been consistently shown to be 
slightly less potent than fulvestrant in cellular assays and 
binding assays, its greater in vivo efficacy is most certainly 
attributable to the markedly higher bioavailability of 
ZB716. This assumption was further confirmed by the 
final plasma concentrations of ZB716 in mice from both 
dose groups where drug concentrations were found to be 
over 6- and 20-fold higher than in the fulvestrant treatment 
Figure 6: Nude mice bearing MCF-7 breast cancer xenograft were treated with either fulvestrant by s.c. injection or 
ZB716 at two different doses PO. Treatment continued for three weeks before the animals were sacrificed and plasma and tumor 
tissues were collected. (A) tumor volumes were plotted vs. days of drug treatment; (B) concentration of ZB716 and fulvestrant in final 
plasma and tumor tissue samples at end of study; (C) WES analysis of ER expression in tumors collected at end of study; and (D) average 
ER expression in tumor tissues at end of study.
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group. Moreover, when tumor tissues were analyzed 
for drug concentrations, we note that ZB716 afforded 
a 4-fold higher drug accumulation level for the 10 mg/
kg dose group, and 10-fold higher drug concentration 
for the 30 mg/kg dose group, than in the fulvestrant 
treated mice. We note that the average downregulation 
of ER in tumor tissues did not appear to be fully in line 
with efficacy, possibly due to the effect of circulating 
estrogen (from implanted E2 pellets) that suppresses ER 
expression to various degrees in tumor tissues. The oral 
efficacy of ZB716 was further verified in the second in 
vivo experiment using a PDX mouse model hosting an 
ER+/PR+/Her2- primary breast tumor (Figure 7) where 
both ZB716 dose groups showed regression of tumor 
comparable to the fulvestrant group. Importantly, in all 
tumor bearing animals treated with different oral doses of 
ZB716, no apparent toxicities were observed in the entire 
course of treatment, and no significant loss or increase of 
animal body weights was recorded.
Figure 7: (A) Inhibition of PDX breast tumors by ZB716 orally administered to mice at 5 and 20 mg/kg, and by fulvestrant 200 mg/kg 
subcutaneously injected at 200 mg/kg weekly. (B) Downregulation of ERα in tumor tissues treated by fulvestrant, ZB716 5mg/kg, or ZB716 
20 mg/kg, respectively.
Table 2: Dose-dependent pharmacokinetics of ZB716 orally administered to rats
Time (hrs)
Rat plasma concentration (ng/mL) of ZB716 after a single oral dose
1 mg/kg 5 mg/kg 10 mg/kg 20 mg/kg
1 14.85±6.51 46.52±4.81 217.66±27.76 1044.53±153.17
3 9.23±2.33 23.37±2.80 93.58±21.77 670.93±125.16
6 4.70±1.66 15.92±2.03 62.04±14.86 370.93±111.46
8 4.42±2.38 11.42±0.52 60.74±13.93 299.84±118.47
24 1.36±1.42 9.37±1.24 33.09±10.58 98.53±36.11
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An important question to be answered with regard to 
the oral bioavailability of ZB716 is whether its systemic 
circulation level is dose-dependent. This is highly relevant 
to both first-line and second-line settings in the clinic. In 
the former, dose optimization to achieve therapeutically 
effective drug levels in patients’ systemic circulation with 
manageable adverse side effects is critical for a long-term 
first line regimen, and dose-dependent oral bioavailability 
enables such optimization. In the latter when ZB716 is 
potentially indicated for second- or third-line endocrine 
treatment, higher drug exposure may be necessary for 
rapid response and maximal clinical benefits in advanced 
breast cancer patients. A four-dose pharmacokinetic study 
(Table 2) demonstrated a favorable dose-response of 
ZB716’s oral bioavailability. The 20 mg/kg dose afforded 
a peak plasma concentration of over 1000 ng/mL, or 1.6 
μM, a level that far exceeds the therapeutically effective 
concentration of a potent SERD with low nanomolar IC50 
values in endocrine sensitive breast cancer cells, and a 
level that is also significantly higher than its IC50 value in 
ER mutant breast cancer cells.
MATERIALS AND METHODS
Molecular modeling
To study interactions of ZB716with ERα, 
computational docking and modeling studies were 
performed using the Glide program in Schrodinger 
Suite 2015-3. The antagonistic ligands induce 
conformational changes on ER
α
 and prevent the binding 
of coactivator signal transmitting proteins, thus impair 
hormone dependent ER transactivation [28]. Since both 
fulvestrant and ZB716 act as ER antagonists, the X-ray 
crystal structure of ERα in complex with an antagonist 
(6-(4-methylsulfonyl-pheynyl)-5-[4-(2-piperidin-1-
ylethoxy)phenoxy]naphthalene-2-ol) with a resolution of 
1.9 Å (PDB entry: 2AYR) was used for binding studies. 
The initial 3D coordinates for ERα was prepared by 
removing all the crystallographic water molecules beyond 
5 Å from the crystal ligand and adding hydrogen atoms 
consistent with physiologic pH of 7 using Maestro 10.3. 
Then the protein molecule was energy minimized with 
an RMSD cutoff value of 0.3 Å for all heavy atoms. The 
ligand molecule, fulvestrant, was prepared by optimizing 
the initial coordinates obtained from the ZINC database 
using Maestro. The structure of ZB716 was prepared 
by replacing the 3-hydroxyl group with a boronic acid 
group followed by energy minimization. The binding 
site for antagonists on the ERα is well characterized by 
the crystallographic studies of ERα in complex with 
various antagonists [21–24]. Thus the antagonist binding 
site-based receptor grid was generated for docking with 
the ER. The ER-ligand docking was then performed 
with Glide 6.8 using default parameters under the extra 
precision (XP) mode allowing the procurement of the best 
docked representative structure. Finally, the binding free 
energies of the complexes were calculated using the MM/
GBSA method with OPLS/AA force field and a GB/SA 
continuum solvent model.
Compound-mediated modulation of ERα-
coregulator interaction
The modulation of ERα-coregulator interaction 
by compound was analyzed using MARCoNI (Micro 
Array Assay for Real-time Coregulator Nuclear receptor 
Interaction) as described previously [29] using 7 nM GST-
tagged ERα LBD (Invitrogen).
In short, a reaction mix with ERα LBD and 
fluorescently labeled detection antibody with 10 μM 
of the indicated compound or solvent (DMSO, 2% 
final concentration) only is incubated on a microarray 
containing 154 coregulator-derived NR-binding motifs. 
Each condition is measured using 3 technical replicates 
(arrays). After incubation, unbound receptor is removed 
by washing, and a tiff image of each array is acquired 
using a CCD camera and receptor binding to each peptide 
on the array is quantified using dedicated software. For 
each condition, the three technical replicates are used 
to calculate mean and S.E.M. ERα binding as well as 
compound-induced log-fold modulation vs. control for 
each individual motif. Significance of the modulation is 
assessed using Student’s t-Test.
T47D Y537S ER mutant cell line
Wild-type ESR1, the Y537S ESR1 mutant were 
fused to a FLAG tag at their C-termini and cloned into 
the lentiviral vector pFLRu-FH [30]. Y537S mutation was 
first introduced into ESR1 using the QuikChange II XL 
Site-Directed Mutagenesis Kit (Agilent) with an ESR1-
encoding plasmid (Accession number NM_000125.1, 
GeneCopoeia Inc.) as the template. A FLAG-tag 
(DYKDDDDK) was then added to the C terminus of 
full-length wild-type and mutant (Y537S) ESR1 by PCR 
amplification, followed by shuttling into the designation 
lentiviral vector pFLRu-FH. To make lentiviral particles, 
pFLRu-FH vector DNAs (encoding ESR1(wt) and 
ESR1(Y537S)) were cotransfected with the packaging 
plasmids into HEK293T cells using Fugene 6 (Roche). 
At 48 hours post transfection, culture media containing 
different viruses were added to T47D cells in the presence 
of polybrene followed by 3-day puromycin selection for 
stable expression. Transgene expression was verified by 
western blot analysis for wild-type and mutant ER mutant 
proteins.
For growth assays in the presence of ZB716 or 
fulvestrant, T47D Y537S ESR1 mutant cells were plated 
in six-well plates at a density of 50,000 each well in 5% 
FBS DMEM medium. The cells were then treated with 
ZB716 or fulvestrant at 5 different doses ranging from 
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10-10 M to 10-6 M for 5 days, while equal volumes of 
DMSO were used as vehicle controls. Viable cell numbers 
were counted with a Z Series Coulter Counter instrument 
(Beckman-Coulter) following manufacturer’s instructions. 
The ratio of drug treated viable cell numbers to vehicle 
treated viable cell numbers was defined as survival ratio 
where the control has the survival ratio of 100%. IC50 
values were obtained from dose-response curves for all 
treatments.
Western blot of ER downregulation
MCF-7 cells were plated at a density of 200,000 
cells/60mm dish. Media containing the same drug 
concentrations as the growth curve assay were added 
on the day following plating (day 0) and allowed to 
incubate for 5 days for Western blot. Media with the tested 
compound was changed every other day. Cells were lysed. 
Lysates were placed on a rotisserie at 4°C for 30 min and 
then spun at 4°C at 12,000 rcf for 10 min. Supernatants 
were assayed for protein content, snap-frozen, and stored 
at -80°C if not run immediately. 50 μg of protein was 
subjected to Western blot protocol. Membranes were 
blocked and then incubated with 1:200 dilution of ERα 
antibody at 4°C overnight followed by 1:10,000 dilution 
of secondary antibody for 1 hr at room temperature. They 
were then imaged on a LICOR infrared scanner.
Total ERα protein levels in T47D Y537S ER mutant 
cells were determined using automated Western blotting 
(Wes Simple Western Analysis, ProteinSimple, San Jose, 
CA). Simple Western analyses were performed according 
to the ProteinSimple user manual. Briefly, T47D Y537S 
ER mutant cells were grown in charcoal stripped serum 
for 6 days and plated at a density of 250,000 cells per well 
in a 12-well plate. Cells were treated with either DMSO, 
ZB716, or fulvestrant at the indicated concentrations for 
four hours, and protein was extracted from cells using 
MPER lysis buffer (Pierce) containing protease and 
phosphatase inhibitors (Thermo Scientific). Samples were 
mixed with a master mix (ProteinSimple) to give a final 
concentration of 0.2 mg/mL total protein, 1×sample buffer, 
S61×fluorescent molecular weight markers, and 40 mM 
DTT. Samples were heated at 95°C for 5 min followed 
by centrifugation. Samples, blocking solution, primary 
antibodies, horseradish peroxidase-conjugated secondary 
antibodies, chemiluminescent substrate, and separation 
and stacking matrices were loaded into designated wells 
in a 384 well plate. After plate loading, fully automated 
electrophoresis and immunodetection took place in the 
capillary system. Proteins were separated by molecular 
weight at 375V for 25 min, and primary and secondary 
antibodies incubated for 30 minutes. The ERα (Santa 
Cruz, cat # sc-543) and actin (Novus, cat #NB600-503) 
antibodies were diluted in a proprietary antibody diluent 
at a 1:50 dilution ratio. Chemiluminescence was captured 
by a charge-coupled device camera, and the digital image 
was analyzed using Compass software (ProteinSimple). 
The relative amount of each protein, relative to total 
protein content, was calculated based on peak area. Total 
ERα levels were normalized to actin. IC50 values were 
obtained from dose-response curves for all treatments.
Efficacy study in an MCF-7 xenograft tumor 
model
Four to six weeks old female ovariectomized Nu/
Nu mice were purchased from Charles River Laboratories 
(Wilmington, MA). MCF-7 cells were cultured and 
harvested in the exponential growth phase using a PBS/
EDTA solution. The animals were injected bilaterally 
in the mammary fat pad (MFP) with 5x106 viable cells 
suspended in 50 μL sterile PBS mixed with 100 μL 
Matrigel (reduced factor; BD Biosciences, Bed- ford, 
MA). 17b-Estradiol pellets (0.72 mg, 60 day release; 
Innovative Research of America, Sarasota, FL) were 
implanted subcutaneously in the lateral area of the neck 
using a precision trochar (10 gages) at the time of cell 
injection. Tumors were allowed to form and at day 15 post 
cell injection mice. After the tumor formed and became 
palpable, the animals were randomized into four groups, 
and treated with vehicle, fulvestrant at 200 mg/kg weekly 
by subcutaneous injection, ZB716 at 10 mg/kg, or 30 
mg/kg by oral gavage. Tumor sizes were monitored and 
recorded every other day for three weeks of treatment 
duration.
Efficacy study in a patient derived xenograft 
(PDX) tumor model
In a patient-derived xenograft (PDX) mouse model 
in which the primary tumor donated by a postmenopausal 
patient was engrafted in NOD scid gamma (NSG™) 
mice (TM00386 PDX model, Jackson Lab). After the 
tumor formed and became palpable, the animals were 
randomized into four groups, and treated with vehicle, 
fulvestrant at 200 mg/kg weekly by subcutaneous 
injection, ZB716 at 5 mg/kg, or 20 mg/kg by oral gavage. 
Tumor sizes were monitored and recorded every other day 
for three weeks of treatment duration.
Pharmacokinetic study (sampling and analysis)
Female Sprague-Dawley rats, weighing between 
350 and 400 g (Charles River Laboratories, Portage, MI) 
were used for the pharmacokinetic study on ZB716. Rats 
were given oral gavage containing 5% dimethyl sulfoxide 
(DMSO), 40% polyethylene glycol 400, 55% saline-
dissolved ZB716, at doses ranging from 1 mg/kg to 20 
mg/kg. After drug administration, blood samples were 
collected from the lateral tail vein of the rat at 1, 3, 6, 8, 
24 h. Rat blood was collected with a capillary into 1.5 mL 
microcentrifuge tubes containing 0.01 mL of 10 % EDTA 
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anticoagulant. Plasma was then separated from cell pellets 
by centrifugation in a refrigerated centrifuge at 4°C and 
transferred to a separate tube. Plasma samples were frozen 
at -80°C until analysis.
The plasma samples of 100 μL each were processed 
for analysis by a TSQ UPLC-MS/MS system. Aliquots 
of 10 μL of 0.5 ng/μl E-Tamoxifen-2C13, N15, 200 μL 
methanol, and 400 μl chloroform were added to the 
plasma in a 1.5 mL centrifuge tube in sequence. The 
sample was vortexed and stored at -20°C for 4 hours, 
followed by sonication in a Branson B3510MT Ultrasonic 
Cleaners for 30 min and centrifuged at 12000 RPM on 
a Heraeus Fresco 21 Refrigerated Micro Centrifuge from 
Thermo Fisher Scientific for 10 min. The supernatant 
was dried with a nitrogen gas flow and suspended 
in 100 μL methanol. Aliquots of 10 μL of the above 
processed samples were injected into a TSQ Vantage 
mass spectrometer connected with a heated electrospray 
ionization probe and a Dionex Ultimat 3000 UHPLC with 
a Hypersil gold column (50x2.1 mm). The probe setting 
and front mass spectrometer setting were controlled as 
follows: spray voltage 3200 voltage, auxiliary gas 10psi, 
vaporizer temperature 365°C, capillary temperature 
300°C, sheath gas 30psi, S-lens RF amplitude 51 voltage. 
The flow gradient was started with initial 30% mobile 
phase A of water with 0.05% formic acid to 1 min, to 
100% mobile phase B of acetonitrile with 0.05% formic 
acid at 8 min, and return to 30% mobile phase A at 13 min.
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